Novartis | NVS - Bénéfice Avant Impôts





Bénéfice Avant Impôts Changement Date
AbbVie USD 5.57B 2.9B 2026-03
Amgen USD 1.51B 2.41B 2025-12
AstraZeneca USD 3.91B 1.28B 2026-03
Bausch Health Companies USD 56M 162M 2025-12
Biogen USD 377.7M 433.7M 2026-03
Bristol-Myers Squibb USD 1.47B 1.64B 2025-12
Canopy Growth CAD -62.26M 60.84M 2025-12
Corcept Therapeutics USD 9.91M 5.33M 2025-12
Drreddys Laboratories INR 15.43B 1.96B 2025-12
Eli Lilly USD 8.27B 1.03B 2025-12
Gilead Sciences USD 2.08B 1.56B 2025-12
GlaxoSmithKline GBP 2.14B 919M 2026-03
Glaxosmithkline GBP 2.46B 569M 2025-09
J&J USD 7.82B 2.86B 2026-03
Merck USD 3.42B 3.32B 2025-12
Novartis USD 3.84B 802M 2026-03
Novartis USD 5.17B 637M 2025-09
Pacira USD 571K 8.95M 2025-12
Perrigo USD -1.33B 1.35B 2025-12
Pfizer USD 5.18B 6.82B 2026-03
Phibro Animal Health USD 38.62M 1.26M 2025-12
Prestige Brands USD 61.81M 7.32M 2025-12
Roche Holding CHF 4.79B 3.01B 2025-06
Sanofi EUR -1.16B 5.5B 2025-12
Sanofi EUR -1.16B 6.23B 2025-12
Supernus Pharmaceuticals USD -5.95M 4.04M 2026-03
Zoetis USD 761M 126M 2025-12